Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Active Moderate to Severe Graves' Orbitopathy”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Looking for participantsNCT07547930
What this trial is testing

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Who this might be right for
Thyroid Eye Disease, TEDGraves OphthalmopathyGraves Orbitopathy
The First Affiliated Hospital of Xiamen University 8
Post-approval studies (Phase 4)Looking for participantsNCT07152340
What this trial is testing

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

Who this might be right for
Thyroid Associated Ophthalmopathies
Shanghai Changzheng Hospital 64
Testing effectiveness (Phase 2)Study completedNCT03110848
What this trial is testing

Effects of Atorvastatin in Graves' Orbitopathy (GO)

Who this might be right for
Thyroid Associated OphthalmopathyHypercholesterolemia
University of Pisa 88
Testing effectiveness (Phase 2)Study completedNCT03922321
What this trial is testing

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Who this might be right for
Graves' Ophthalmopathy
Immunovant Sciences GmbH 7
Large-scale testing (Phase 3)Not Yet RecruitingNCT07622108
What this trial is testing

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

Who this might be right for
Thyroid Eye Disease, TED
Minghui Pharmaceutical (Hangzhou) Ltd 84
Large-scale testing (Phase 3)WithdrawnNCT02422368
What this trial is testing

The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease

Who this might be right for
Thyroid Eye Disease
Iran University of Medical Sciences
Large-scale testing (Phase 3)Active Not RecruitingNCT06248619
What this trial is testing

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Who this might be right for
Thyroid Eye Disease
Amgen 89
Post-approval studies (Phase 4)Not Yet RecruitingNCT03098225
What this trial is testing

A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy

Who this might be right for
Thyroid Associated Ophthalmopathy
University of Pisa 120
Testing effectiveness (Phase 2)Ended earlyNCT05394857
What this trial is testing

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Who this might be right for
Active Moderate to Severe Graves' Orbitopathy
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 7
Not applicableStudy completedNCT05793359
What this trial is testing

Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy

Who this might be right for
Graves Ophthalmopathy
Medical University of Sofia 62
Not applicableStudy completedNCT06367517
What this trial is testing

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Who this might be right for
Orbitopathy, GravesThyroid Eye DiseaseOphthalmopathy
Medical University of Warsaw 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07720635
What this trial is testing

A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease

Who this might be right for
Thyroid Eye Disease
Beijing Kanghong Biological Medicine Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06401044
What this trial is testing

AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Who this might be right for
Thyroid Eye Disease
Amgen 94
Large-scale testing (Phase 3)Looking for participantsNCT06989918
What this trial is testing

MHB018A Treatment in Patients With Active Thyroid Eye Disease

Who this might be right for
Thyroid Associated Ophthalmopathies
Minghui Pharmaceutical (Hangzhou) Ltd 108
Testing effectiveness (Phase 2)Study completedNCT01727973
What this trial is testing

Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

Who this might be right for
Graves OphthalmopathyGraves DiseaseEye Diseases+6 more
Sun Yat-sen University 14
Large-scale testing (Phase 3)Ended earlyNCT04737330
What this trial is testing

The Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Who this might be right for
Thyroid Eye DiseaseGraves Orbitopathy
Novartis Pharmaceuticals 28
Very early researchUnknownNCT05532072
What this trial is testing

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

Who this might be right for
Graves Ophthalmopathy
First Affiliated Hospital Xi'an Jiaotong University 140
Testing effectiveness (Phase 2)UnknownNCT04598815
What this trial is testing

Sirolimus for Graves' Orbitopathy (GO)

Who this might be right for
Graves Ophthalmopathy
University of Pisa 54
Not applicableStudy completedNCT05345119
What this trial is testing

Sirolimus in Graves' Orbitopathy

Who this might be right for
Graves Ophthalmopathy
University of Pisa 30
Large-scale testing (Phase 3)Looking for participantsNCT06112340
What this trial is testing

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Who this might be right for
Thyroid Eye DiseaseGraves OrbitopathyEndocrine System Diseases+9 more
Sling Therapeutics, Inc. 75
Next Page